Under the category of the OTC/Nutraceutical products are listed the products which are sold without prescription. Members of Farmavita.net are invited to publish their out-license offers in this Category.

NCE for oncology - Improved HDAC inhibitors



NCE for oncology - Improved HDAC inhibitors

Ikerchem offers two promising anticancer drugs with best in class attributes available for in licensing.
If you are interested in acquiring or co-developing oncology products with excellent solid tumor activity
and optimum safety profile, please, read the offer below.

IKH02 is currently at the late preclinical stage and is a novel oral HDAC pan-inhibitor with amazing toxicological/safety
profile and excellent PK/activity data. No/little side effects are expected to occur in clinical phases, while real responses
in solid and hematologic tumors are foreseen. IND filing is expected for Q1 2012.

IKH25 is a hundred-fold selective HDAC6 inhibitor, whose IND filing is expected for Q4 2012.
Great activity in solid tumors has been observed. This compound showed excellent PK, toxicity and activity profiles.

Ikerchem is also developing best in class DNMT, Proteasome and JMJ inhibitors, which are now at the lead optimization stage.

For more information please contact me at:


More details

Name Description
Pharma licensing Out-licensing (offer)

Ad details

Ad ID : 766

Advertiser details

Contact Advertiser

Add comment


Contact form

Sorry, you need to register or login first.

What's wrong with this ad?

Sorry, you need to register or login first.

Add to favourites

Sorry, you need to register or login first.

Advert search

Recent adverts

Lokking for EU CTD Dossiers for traditional...
Member of  Farmavita.Net from EU is looking to...
We are looking to acquire Azathioprine tablet...
I am looking for a good quality dossier with...
We offer for outlicensing European e-CTD...
Novel herbal based throat pastilles with...
We are looking for EU-CTD dossier...